AR046103A1 - Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion - Google Patents
Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicionInfo
- Publication number
- AR046103A1 AR046103A1 ARP040103693A ARP040103693A AR046103A1 AR 046103 A1 AR046103 A1 AR 046103A1 AR P040103693 A ARP040103693 A AR P040103693A AR P040103693 A ARP040103693 A AR P040103693A AR 046103 A1 AR046103 A1 AR 046103A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycloalkyl
- heteroaryl
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Abstract
Un compuesto de 8-azoniabiciclo[3.2.1]octano que tiene la estructura de fórmula (1) o (2), excepto el compuesto de fórmula (2) en la que R2 y R3 son 2-tiofeno y R4 es -OC(O)CH3, en las cuales: el átomo de H indicado está en la posición exo; R1- representa un anión asociado con la carga positiva del átomo de N. R1- puede ser, pero sin estar limitado a ello, cloruro, bromuro, yoduro, sulfato, benceno-sulfonato y tolueno-sulfonato; R2 y R3 se seleccionan independientemente entre el grupo que consiste en grupos alquilo inferior de cadena lineal o ramificada (que tienen preferentemente C1-6), grupos cicloalquilo (C5-6), cicloalquil-alquilo(C6-10), heterocicloalquilo (C5-6), y N u O como el heteroátomo, heterocicloalquil-alquilo(C6-10) y N u O como el heteroátomo, arilo, arilo opcionalmente sustituido, heteroarilo y heteroarilo opcionalmente sustituido; R4 se selecciona entre el grupo que consiste en alquilo (C1-6), cicloalquilo (C3-12), heterocicloalquilo (C3-7), alquil(C1-6)- cicloalquilo(C3-12), alquil(C1-6)-heterocicloalquilo(C3-7), arilo, heteroarilo, alquil(C1-6)-arilo, alquil(C1-6)-heteroarilo, -OR5, -CH2OR5, -CH2OH, -CN, -CF3, -CH2O(CO)R6, -CO2R7, -CH2NH2, -CH2N(R7)SO2R5, -SO2N(R7)(R8), -CON(R7)(R8), - CH2N(R8)CO(R6), -CH2N(R8)SO2(R6), -CH2N(R8)CO2(R5), -CH2N(R8)CONH(R7); R5 se selecciona entre el grupo que consiste alquilo (C1-6), alquil(C1-6)-cicloalquilo(C3-12), alquil(C1-6)-heterocicloalquilo(C3-7), aqluil(C1-6)-arilo o alquil(C1-6)- heteroarilo; R6 se selecciona entre el grupo que consiste en alquilo (C1-6), cicloalquilo (C3-12), heterocicloalquilo (C3-7), alquil(C1-6)-cicloalquilo(C3-12), alquil(C1-6)-heterocicloalquilo(C3-7), arilo, heteroarilo,l alquil(C1-6)-arilo o alquil(C1-6)-heteroarilo; R7 y R8 se seleccionan, independientemente, entre el grupo que consiste en H, alquilo (C1-6), cicloalquilo (C3-12), heterocicloalquilo (C3-7), alquil(C1-6)-cicloalquilo(C3-12), alquil(C1-6)-heterocicloalquilo(C3-7), alquil(C1-6)-arilo o alquil(C1-6)-heteroarilo. Composición farmacéutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarínicos, que comprende dicho compuesto y un vehículo farmacéuticamente aceptable para el mismo. Uso del compuesto para preparar una composición farmacéutica de utilidad para tratar una enfermedad mediada por receptores de acetilcolina muscarínicos, en la que la acetilcolina se une a dicho receptor, mediante la administración de una cantidad segura y eficaz de dicho compuesto. La mencionada enfermedad puede ser enfermedad crónica de obstrucción pulmonar, bronquitis crónica, asma, obstrucción respiratoria crónica, fibrosis pulmonar, enfisema pulmonar y rinitis alérgica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51100903P | 2003-10-14 | 2003-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046103A1 true AR046103A1 (es) | 2005-11-23 |
Family
ID=34465175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103693A AR046103A1 (es) | 2003-10-14 | 2004-10-12 | Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion |
Country Status (34)
Country | Link |
---|---|
US (3) | US7276521B2 (es) |
EP (1) | EP1677795B1 (es) |
JP (4) | JP2007508390A (es) |
KR (3) | KR20080065318A (es) |
CN (3) | CN101230062A (es) |
AP (3) | AP1828A (es) |
AR (1) | AR046103A1 (es) |
AT (1) | ATE494285T1 (es) |
AU (1) | AU2004281724B2 (es) |
BR (1) | BRPI0415361A (es) |
CA (1) | CA2542657C (es) |
CY (1) | CY1111364T1 (es) |
DE (1) | DE602004030930D1 (es) |
DK (1) | DK1677795T3 (es) |
EA (3) | EA013435B1 (es) |
EC (1) | ECSP066468A (es) |
ES (1) | ES2358673T3 (es) |
HR (1) | HRP20110232T1 (es) |
IL (2) | IL174843A0 (es) |
IS (1) | IS2918B (es) |
MA (1) | MA28110A1 (es) |
MX (1) | MXPA06004244A (es) |
MY (1) | MY143366A (es) |
NO (1) | NO20062042L (es) |
NZ (2) | NZ556424A (es) |
OA (1) | OA13316A (es) |
PE (1) | PE20050963A1 (es) |
PL (1) | PL1677795T3 (es) |
PT (1) | PT1677795E (es) |
SG (1) | SG147436A1 (es) |
SI (1) | SI1677795T1 (es) |
TW (3) | TW200811172A (es) |
UA (2) | UA89734C2 (es) |
WO (1) | WO2005037280A1 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20050250A1 (es) * | 2003-07-17 | 2005-04-08 | Glaxo Group Ltd | Antagonistas de los receptores muscarinicos de la acetilcolina |
AR046103A1 (es) * | 2003-10-14 | 2005-11-23 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion |
AR046114A1 (es) * | 2003-10-17 | 2005-11-23 | Glaxo Group Ltd | Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion |
TW200524577A (en) * | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
JP2007528420A (ja) * | 2004-03-11 | 2007-10-11 | グラクソ グループ リミテッド | 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト |
EP1725238A4 (en) * | 2004-03-17 | 2009-04-01 | Glaxo Group Ltd | ACETYLCHOLINE M 3 MUSCARINIC RECEPTOR ANTAGONISTS |
WO2005095407A1 (en) * | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
UY28871A1 (es) | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | Antagonistas del receptor de acetilcolina muscarinico |
EP1747219A4 (en) * | 2004-05-13 | 2010-05-26 | Glaxo Group Ltd | Antagonists of muscarinic acetylcholine receptor |
JP2008520579A (ja) * | 2004-11-15 | 2008-06-19 | グラクソ グループ リミテッド | 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト |
JP2009503099A (ja) * | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | M3ムスカリン性アセチルコリン受容体アンタゴニスト |
JP2009504768A (ja) * | 2005-08-18 | 2009-02-05 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
US7943651B2 (en) | 2006-04-20 | 2011-05-17 | Glaxo Group Limited | Compounds |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
PL2046787T3 (pl) | 2006-08-01 | 2011-10-31 | Glaxo Group Ltd | Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4 |
JP5498168B2 (ja) * | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体 |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
KR20100063116A (ko) * | 2007-09-12 | 2010-06-10 | 글락소 그룹 리미티드 | 치료제들의 복합제 |
TW200946526A (en) | 2008-02-06 | 2009-11-16 | Glaxo Group Ltd | Dual pharmacophores-PDE4-muscarinic antagonistics |
AR070563A1 (es) | 2008-02-06 | 2010-04-21 | Glaxo Group Ltd | Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias. |
PE20091552A1 (es) | 2008-02-06 | 2009-10-25 | Glaxo Group Ltd | Farmacoforos duales - antagonistas muscarinicos de pde4 |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
WO2010097114A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Novel combination of therapeutic agents |
SI2400950T1 (sl) | 2009-02-26 | 2019-09-30 | Glaxo Group Limited | Farmacevtske forlmulacije, ki obsegajo 4-((1 R)-2-((6-(2-((2,6- diklorobenzil)oksi)etoksi)heksil)amino)-1-hidroksietil)-2- (hidroksimetil)fenol |
EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Itk阻害剤として使用されるピリミジン誘導体 |
HUE034724T2 (hu) | 2009-04-30 | 2018-02-28 | Glaxo Group Ltd | Oxazol-szubsztituált indazolok mint PI3-kináz inhibitorok |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
EP2507226A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Novel compounds |
EP2507223A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
DK2614058T3 (en) | 2010-09-08 | 2015-09-28 | Glaxosmithkline Ip Dev Ltd | Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide. |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
ES2814336T3 (es) | 2012-04-13 | 2021-03-26 | Glaxosmithkline Ip Dev Ltd | Partículas de agregado |
GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
AU2014336251A1 (en) | 2013-10-17 | 2016-04-14 | Glaxosmithkline Intellectual Property Development Limited | PI3K inhibitor for treatment of respiratory disease |
JP2016537327A (ja) | 2013-10-17 | 2016-12-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 呼吸器疾患の治療のためのpi3k阻害剤 |
EP3142694A2 (en) | 2014-05-12 | 2017-03-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
EP3497100A1 (en) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2800478A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
US2800481A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
US2800482A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | Olefinic derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
AT298118B (de) * | 1967-06-08 | 1972-04-25 | Siemens Ag | Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens |
GB2064336B (en) | 1979-12-06 | 1984-03-14 | Glaxo Group Ltd | Device for dispensing medicaments |
ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
AU570013B2 (en) | 1982-10-08 | 1988-03-03 | Glaxo Group Limited | Medicament inhaler |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
GB8923590D0 (en) * | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
GB9000304D0 (en) * | 1990-01-06 | 1990-03-07 | Pfizer Ltd | Muscarinic receptor antagonists |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
JP3294961B2 (ja) * | 1993-12-10 | 2002-06-24 | 杏林製薬株式会社 | 新規イミダゾール誘導体及びその製造法 |
JPH08291141A (ja) * | 1995-04-21 | 1996-11-05 | Kotobuki Seiyaku Kk | ジフェニル酢酸誘導体及びその製造法 |
JPH0920758A (ja) * | 1995-07-06 | 1997-01-21 | Kyorin Pharmaceut Co Ltd | 新規環状ジアミン誘導体及びその製造法 |
JP2001505576A (ja) | 1996-12-02 | 2001-04-24 | ジョージタウン ユニバーシティ | トロパン誘導体類及びそれらの合成方法 |
US6248752B1 (en) | 1998-02-27 | 2001-06-19 | Charles Duane Smith | Azabicyclooctane compositions and methods for enhancing chemotherapy |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
IL160896A0 (en) * | 2001-10-17 | 2004-08-31 | Ucb Sa | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
US6696462B2 (en) | 2002-01-31 | 2004-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions |
DE10211700A1 (de) * | 2002-03-16 | 2003-09-25 | Boehringer Ingelheim Pharma | Neue Difurylglykolsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
AR040779A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion |
EP1613307A4 (en) | 2003-04-07 | 2008-03-12 | Glaxo Group Ltd | M SB 3 / SB MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS |
PE20050250A1 (es) | 2003-07-17 | 2005-04-08 | Glaxo Group Ltd | Antagonistas de los receptores muscarinicos de la acetilcolina |
TW200519109A (en) | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
UY28417A1 (es) | 2003-07-17 | 2005-02-28 | Glaxo Group Ltd | Antagonistas de los receptores muscarinicos de la acetilcolina |
AR046103A1 (es) * | 2003-10-14 | 2005-11-23 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion |
TW200524577A (en) * | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
JP4851937B2 (ja) * | 2003-11-21 | 2012-01-11 | セラヴァンス, インコーポレーテッド | β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
US20090258858A1 (en) | 2004-10-29 | 2009-10-15 | Jakob Busch-Petersen | Muscarinic acetylcholine receptor antagonists |
JP2008520579A (ja) | 2004-11-15 | 2008-06-19 | グラクソ グループ リミテッド | 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト |
WO2006055503A2 (en) | 2004-11-15 | 2006-05-26 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
PE20060826A1 (es) | 2004-12-06 | 2006-10-08 | Smithkline Beecham Corp | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende |
PE20061162A1 (es) | 2004-12-06 | 2006-10-14 | Smithkline Beecham Corp | Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos |
WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
WO2006065788A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Novel muscarinic acetylcholine receptor antagonists |
WO2007018508A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetycholine receptor antagonists |
WO2007018514A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
JP2009503099A (ja) | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | M3ムスカリン性アセチルコリン受容体アンタゴニスト |
JP2009503101A (ja) | 2005-08-02 | 2009-01-29 | グラクソ グループ リミテッド | M3ムスカリン性アセチルコリン受容体アンタゴニスト |
JP2009504768A (ja) | 2005-08-18 | 2009-02-05 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
-
2004
- 2004-10-12 AR ARP040103693A patent/AR046103A1/es not_active Application Discontinuation
- 2004-10-12 PL PL04794886T patent/PL1677795T3/pl unknown
- 2004-10-12 SI SI200431631T patent/SI1677795T1/sl unknown
- 2004-10-12 EA EA200702617A patent/EA013435B1/ru not_active IP Right Cessation
- 2004-10-12 UA UAA200900439A patent/UA89734C2/ru unknown
- 2004-10-12 KR KR1020087016101A patent/KR20080065318A/ko not_active Application Discontinuation
- 2004-10-12 MX MXPA06004244A patent/MXPA06004244A/es active IP Right Grant
- 2004-10-12 SG SG200807641-6A patent/SG147436A1/en unknown
- 2004-10-12 US US10/575,839 patent/US7276521B2/en not_active Expired - Fee Related
- 2004-10-12 KR KR1020087016103A patent/KR20080067023A/ko not_active Application Discontinuation
- 2004-10-12 AU AU2004281724A patent/AU2004281724B2/en not_active Ceased
- 2004-10-12 CA CA2542657A patent/CA2542657C/en not_active Expired - Fee Related
- 2004-10-12 CN CNA2008100092900A patent/CN101230062A/zh active Pending
- 2004-10-12 EA EA200702619A patent/EA013689B1/ru not_active IP Right Cessation
- 2004-10-12 ES ES04794886T patent/ES2358673T3/es active Active
- 2004-10-12 OA OA1200600122A patent/OA13316A/en unknown
- 2004-10-12 BR BRPI0415361-8A patent/BRPI0415361A/pt not_active Application Discontinuation
- 2004-10-12 PE PE2004000982A patent/PE20050963A1/es not_active Application Discontinuation
- 2004-10-12 DK DK04794886.4T patent/DK1677795T3/da active
- 2004-10-12 AP AP2006003566A patent/AP1828A/xx active
- 2004-10-12 TW TW096137868A patent/TW200811172A/zh unknown
- 2004-10-12 DE DE602004030930T patent/DE602004030930D1/de active Active
- 2004-10-12 CN CNA2008100092898A patent/CN101230061A/zh active Pending
- 2004-10-12 EA EA200600773A patent/EA200600773A1/ru not_active IP Right Cessation
- 2004-10-12 KR KR1020067007082A patent/KR20060106821A/ko not_active Application Discontinuation
- 2004-10-12 AP AP2007004239A patent/AP2007004239A0/xx unknown
- 2004-10-12 AP AP2007004238A patent/AP2007004238A0/xx unknown
- 2004-10-12 NZ NZ556424A patent/NZ556424A/en unknown
- 2004-10-12 NZ NZ546312A patent/NZ546312A/en unknown
- 2004-10-12 PT PT04794886T patent/PT1677795E/pt unknown
- 2004-10-12 TW TW096137867A patent/TW200811171A/zh unknown
- 2004-10-12 JP JP2006535591A patent/JP2007508390A/ja active Pending
- 2004-10-12 WO PCT/US2004/033638 patent/WO2005037280A1/en active Application Filing
- 2004-10-12 MY MYPI20044177A patent/MY143366A/en unknown
- 2004-10-12 CN CNA2004800372668A patent/CN1893948A/zh active Pending
- 2004-10-12 EP EP04794886A patent/EP1677795B1/en active Active
- 2004-10-12 TW TW093130797A patent/TWI409060B/zh not_active IP Right Cessation
- 2004-10-12 UA UAA200604113A patent/UA87473C2/ru unknown
- 2004-10-12 AT AT04794886T patent/ATE494285T1/de active
-
2006
- 2006-03-31 EC EC2006006468A patent/ECSP066468A/es unknown
- 2006-04-06 IL IL174843A patent/IL174843A0/en unknown
- 2006-04-25 MA MA28964A patent/MA28110A1/fr unknown
- 2006-05-05 IS IS8441A patent/IS2918B/is unknown
- 2006-05-08 NO NO20062042A patent/NO20062042L/no not_active Application Discontinuation
-
2007
- 2007-06-21 US US11/766,371 patent/US7576096B2/en not_active Expired - Fee Related
- 2007-06-21 US US11/766,318 patent/US7579361B2/en not_active Expired - Fee Related
- 2007-08-02 JP JP2007201718A patent/JP4796552B2/ja not_active Expired - Fee Related
- 2007-08-02 JP JP2007201719A patent/JP2007314567A/ja active Pending
- 2007-12-13 IL IL188112A patent/IL188112A/en not_active IP Right Cessation
-
2011
- 2011-03-30 CY CY20111100339T patent/CY1111364T1/el unknown
- 2011-03-31 HR HR20110232T patent/HRP20110232T1/hr unknown
- 2011-05-16 JP JP2011109756A patent/JP5450509B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046103A1 (es) | Compuesto de 8-azoniabiciclo [3.2.1] octano,composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion | |
AR050902A1 (es) | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion | |
ES2599458T3 (es) | Compuestos y métodos de uso | |
AR046114A1 (es) | Compuesto de 8- azoniabiciclo (3.2.1) octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos y uso del compuesto para preparar dicha composicion | |
AR042583A1 (es) | Macrolidos | |
AR060618A1 (es) | Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo | |
PE20010397A1 (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 y composiciones farmaceuticas que los contienen | |
AR068757A2 (es) | Ligandos derivados de piperidina de alta afinidad para el receptor de nociceptina orl-1; composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos | |
AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
BR0012801A (pt) | Agonistas orl-1 receptores de nociceptina para uso no tratamento da tosse | |
CO5680443A2 (es) | Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos | |
ZA200410213B (en) | Indole derivatives useful as histamine H3 antagonists. | |
AR059481A1 (es) | Derivados de 1, 3-dihidro-imidazo[4, 5-c]piridin-2-ona como agonista del receptor tlr7, un metodo para su preparacion, intermediarios de sintesis de los mismos, una composicion farmaceutica que los comprende y su uso en la elaboracion de un medicamento para el tratamiento de infecciones viricas. | |
ES2524910T3 (es) | Piperidino-dihidrotienopirimidinas sustituidas | |
AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos | |
PE20061162A1 (es) | Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos | |
BR0314392A (pt) | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação | |
AR046225A1 (es) | Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion | |
AR048266A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende y su uso para prepararla | |
AR046783A1 (es) | Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
CN102596949B (zh) | 8-氮杂双环[3.2.1]辛烷-8-甲酰胺衍生物 | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
BR0317645A (pt) | Composto ou um sal deste, composição farmacêutica, uso de um composto, e, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deterioração cognitiva em um mamìfero | |
AR045914A1 (es) | Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
AR044006A1 (es) | Compuesto de fenilpiperidinilo, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed, e.g., due to non-payment of fee |